Venomous animals have a long history as a source of medical treatments (1). Snake venom, for example, has been used in Ayurvedic medicine since the 7th century BCE to prolong life and treat arthritis and gastrointestinal ailments. Tarantulas are used by indigenous populations of Central and South America to treat ailments ranging from asthma to cancer, while cobra venom has been used since the 1930s to treat conditions as diverse as asthma, polio, multiple sclerosis, rheumatism and pain (2). However, the modern era of venoms-based drug discovery did not begin until the 1970s with the development of the blockbuster antihypertensive drug captopril, based on a peptide from the venom of the Brazilian viper Bothrops jaracaca (3). Today, many of the major pharmaceutical companies (and most major agrochemical companies) have venom-based drug discovery programs or use venom-derived molecules for target validation (e.g., AstraZeneca, Eli Lilly, Johnson & Johnson and Merck). Moreover, there are now several companies with a focus on venom-derived therapeutics, including Airmid, ReceptoPharm (a subsidiary of Nutra Pharma), Theralpha, VenomeTech, Venomics (a subsidiary of QRxPharma) and Xenome. In this article, I outline recent developments in the venoms-based drug discovery field that might lead to new venom-derived peptide therapeutics.